Valuation : C4 Therapeutics, Inc.

Market Cap 463M 398M 375M 342M 640M 43.7B 642M 4.43B 1.72B 22.4B 1.74B 1.7B 72.21B P/E 2026 *
-4.34x
P/E 2027 * -3.91x
Enterprise Value 463M 398M 375M 342M 640M 43.7B 642M 4.43B 1.72B 22.4B 1.74B 1.7B 72.21B EV / Sales 2026 *
18x
EV / Sales 2027 * 22.5x
Free-Float
99.17%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : C4 Therapeutics, Inc.

1 day+0.53%
1 week-2.34%
Current month+1.35%
1 month+3.30%
3 months-2.34%
6 months+23.68%
Current year+96.86%
1 week 3.66
Extreme 3.6602
4.07
1 month 3.6
Extreme 3.6
4.38
Current year 1.69
Extreme 1.6901
5.17
1 year 1.69
Extreme 1.6901
5.17
3 years 1.06
Extreme 1.06
11.88
5 years 1.06
Extreme 1.06
51.21
10 years 1.06
Extreme 1.06
51.21
Manager TitleAgeSince
Chief Executive Officer 55 02/10/2020
Director of Finance/CFO 49 18/09/2023
Chief Tech/Sci/R&D Officer 56 28/10/2024
Director TitleAgeSince
Director/Board Member 74 01/12/2015
Director/Board Member 55 14/09/2020
Director/Board Member 55 16/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
10/07/26 Exercice

Chief Technology Officer

22,722 0.0206%
01/07/26 Free

Director

3,341 0.0030%
01/07/26 Free

Founder

2,650 0.0024%
Change 5-day change 1-year change 3-year change Capi.($)
+0.53%-2.34%+38.24%+57.98% 463M
-2.54%-2.84%-1.77%+14.33% 48.93B
-0.40%+1.03%+418.57%+527.30% 45.01B
-1.42%+2.30%+42.67%+22.37% 44.07B
-1.22%-2.31%+4.82%+77.49% 40.73B
+0.53%-1.36%+16.87%+47.12% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+120.75% 16.5B
-1.01%+0.50%+13.91%+31.83% 14.67B
-1.65%-1.03%+75.93%+41.12% 13.77B
Average -0.77%+0.25%+70.07%+104.48% 27.55B
Weighted average by Cap. -1.03%+0.11%+89.33%+128.89%

Financials

2026 *2027 *
Net sales 25.74M 22.16M 20.84M 19.04M 35.6M 2.43B 35.71M 246M 95.52M 1.25B 96.65M 94.54M 4.02B 20.54M 17.68M 16.63M 15.19M 28.41M 1.94B 28.5M 197M 76.22M 995M 77.12M 75.44M 3.21B
Net income -116M -100M -94.2M -86.05M -161M -10.99B -161M -1.11B -432M -5.63B -437M -427M -18.16B -151M -130M -122M -112M -209M -14.29B -210M -1.45B -561M -7.33B -568M -556M -23.61B
Net Debt - -
Logo C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Employees
104
Date Price Change Volume
04/09/26 $3.760 +0.53% 2,363,367
03/09/26 $3.740 -1.32% 2,228,464
02/09/26 $3.790 -2.07% 1,835,390
01/09/26 $3.870 +4.31% 2,364,277
31/08/26 $3.710 -3.64% 1,857,546
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.760USD
Average target price
13.33USD
Spread / Average Target
+254.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CCCC Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!